These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1696065)

  • 1. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost].
    Maekawa M; Kishimoto T; Yasumoto R; Wada S; Harada T; Ohara T; Okajima E; Hirao Y; Ohzono S; Shimada K
    Hinyokika Kiyo; 1990 Apr; 36(4):495-516. PubMed ID: 1696065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
    Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S
    Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of Cernilton in benign prostatic hypertrophy].
    Hayashi J; Mitsui H; Yamakawa G; Suga A; Kai A; Shimabukuro T; Yanagi K; Fujisawa S; Takihara H; Kaneda Y
    Hinyokika Kiyo; 1986 Jan; 32(1):135-41. PubMed ID: 2421560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of Cernilton on benign prostatic hyperplasia].
    Ueda K; Jinno H; Tsujimura S
    Hinyokika Kiyo; 1985 Jan; 31(1):187-91. PubMed ID: 2581428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy].
    Horii A; Iwai S; Maekawa M; Tsujita M
    Hinyokika Kiyo; 1985 Apr; 31(4):739-46. PubMed ID: 2412423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study.
    Yamaguchi O; Shiraiwa Y; Kobayashi M; Yokota T; Ohinata M; Aoki H; Tsuzuki T; Ohori M
    Urol Int; 1990; 45 Suppl 1():40-6. PubMed ID: 1690481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
    Kumamoto Y; Yokoyama E; Tsukamoto T; Tsuchida S; Nishizawa O; Koshiba K; Ishibashi A; Ogawa A; Tomita Y; Aso Y
    Hinyokika Kiyo; 1987 Oct; 33(10):1681-702. PubMed ID: 2451409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study].
    Koyanagi T; Togashi M; Maru A; Orikasa S; Soma F; Shimazaki J; Yasuda K; Aso Y; Honma Y; Miyake K
    Hinyokika Kiyo; 1990 Oct; 36(10):1233-52. PubMed ID: 1979900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of PPC for nonspecific chronic prostatitis].
    Okada S; Hamada K; Takasaki N; Demura A; Okano H; Kirime S; Noda H; Ono S; Akita Y; Nishimoto K
    Hinyokika Kiyo; 1985 Jan; 31(1):179-85. PubMed ID: 3887870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy--comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker].
    Katsumi T; Murayama K
    Hinyokika Kiyo; 1992 Sep; 38(9):1089-92. PubMed ID: 1384297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia].
    Vontobel HP; Herzog R; Rutishauser G; Kres H
    Urologe A; 1985 Jan; 24(1):49-51. PubMed ID: 2580383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The conservative treatment of prostatic hypertrophy with Paraprost].
    Aito K; Watsubo E
    Hinyokika Kiyo; 1972 Jan; 18(1):41-4. PubMed ID: 4112552
    [No Abstract]   [Full Text] [Related]  

  • 14. Cernilton for benign prostatic hyperplasia.
    Wilt T; Mac Donald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2000; (2):CD001042. PubMed ID: 10796739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia.
    MacDonald R; Ishani A; Rutks I; Wilt TJ
    BJU Int; 2000 May; 85(7):836-41. PubMed ID: 10792162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effect of PPC for the palliative treatment of benign prostatic hypertrophy].
    Ishigami J; Kuroda K
    Hinyokika Kiyo; 1969 Jan; 15(1):68-75. PubMed ID: 4180035
    [No Abstract]   [Full Text] [Related]  

  • 17. WITHDRAWN: Cernilton for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2011 May; 2011(5):CD001042. PubMed ID: 21563128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia].
    Fujita T; Ohshima S; Asano H; Ono Y; Kinukawa T; Kato N; Hirabayashi S
    Hinyokika Kiyo; 1992 May; 38(5):613-21. PubMed ID: 1376962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BPH pharmacotherapy (miscellaneous)].
    Okada H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():367-72. PubMed ID: 12599602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.